TTrialPathMatch Me to Trials
← Back to trials
RecruitingType 2 Diabetes MellitusAcute Kidney InjuryChronic Kidney Diseases

Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes

Eligible age

30–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This pilot study will evaluate the feasibility of using a clinical decision support(CDS) message to support consideration of SGLT2 inhibitor prescribing in patients with type 2 diabetes who recently had acute kidney injury. Participating M Health Fairview primary care clinics will be randomized to either receive the clinical decision support intervention or continue usual care. In intervention clinics, providers or clinic pharmacists will receive a message before a scheduled encounter with an eligible patient. The message is intended to support clinical decision-making about SGLT2 inhibitor use, but prescribing decisions will remain with the patient's usual clinical care team. The study will assess feasibility outcomes, including identification of eligible patients, delivery of clinical decision support (CDS) messages, provider/pharmacist receipt of CDS messages, SGLT2i consideration, SGLT2i prescribing, and availability of follow-up kidney function data in the electronic health record.

Sponsor: University of Minnesota

You may qualify if…

  • ✓ Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
  • ✓ Assigned to work in one of the participating study clinics
  • ✓ Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
  • ✓ Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
  • ✓ Medical history of type 2 diabetes mellitus (by billing code)
  • ✓ Age 30 to 75 years at the date of study enrollment
  • ✓ Available eGFR from labs more than 3 business days before the scheduled appointment and after AKI onset that is at least 30 mL/min/1.73 m²
  • ✓ Either a serum creatinine lab measured after discharge from the hospitalization including the AKI, or the last serum creatinine lab during the hospitalization with AKI is less than 0.3 mg/dL above the patient's baseline serum creatinine concentration

You may not qualify if…

  • ✕ None
  • ✕ Opted out of research use of AHC/M Health Fairview data shelter data
  • ✕ History of kidney transplantation as a recipient(by billing code)
  • ✕ Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
  • ✕ SGLT2i allergy in the EHR allergy list
  • ✕ Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
  • ✕ Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by billing code)
  • ✕ Serum creatinine rise of at least 0.3 mg/dL between the two most recent serum creatinine measurements

Where it's recruiting

Minnesota

Minneapolis

Source: ClinicalTrials.gov · NCT07868666 · last updated 2026-11-04

Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes · TrialPath